ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs. ADIENNE aims to develop a range of product candidates for orphan diseases for which existing treatment options are limited, the patient population is small and the clinical needs for therapies is high. |
NEW PARTNERSHIP WITH ACCORD FOR COMMERCIALIZATION OF TEPADINA® We are proud to announce that on November 19, 2019 ADIENNE Pharma & Biotech SA and ACCORD HEALTHCARE Ltd have entered into an exclusive licensing and distribution agreement for the commercialization of TEPADINA® 15 mg and 100 mg lyophilized powder for injections. Click HERE to read the full news. |
ADIENNE GRANTED AIFA MANUFACTURING AUTHORIZATION Following inspection performed by AIFA (Agenzia Italiana del Farmaco) last December, on February 12, 2019 ADIENNE has been granted the authorization n. aM - 12/2019 for the manufacturing of investigational biotech products at its plant located in Caponago (Italy). |